Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models

Dietlinde Wolf, Cameron S. Bader, Henry Barreras, Sabrina Copsel, Brent Pfeiffer, Casey O. Lightbourn, Norman H. Altman, Krishna V Komanduri, Robert B Levy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Posttransplant cyclophosphamide (PTCy) has been found to be effective in ameliorating acute graft-versus-host disease (GVHD) in patients following allogeneic hematopoietic stem cell transplantation (aHSCT). Adoptive transfer of high numbers of donor Tregs in experimental aHSCT has shown promise as a therapeutic modality for GVHD regulation. We recently described a strategy for in vivo Treg expansion targeting two receptors: TNFRSF25 and CD25. To date, there have been no direct comparisons between the use of PTCy and Tregs regarding outcome and immune reconstitution within identical groups of transplanted mice. Here, we assessed these two strategies and found both decreased clinical GVHD and improved survival long term. However, recipients transplanted with Treg-expanded donor cells (TrED) exhibited less weight loss early after HSCT. Additionally, TrED recipients demonstrated less thymic damage, significantly more recent thymic emigrants, and more rapid lymphoid engraftment. Three months after HSCT, PTCy-treated and TrED recipients showed tolerance to F1 skin allografts and comparable immune function. Overall, TrED was found superior to PTCy with regard to weight loss early after transplant and initial lymphoid engraftment. Based on these findings, we speculate that morbidity and mortality after transplant could be diminished following TrED transplant into aHSCT recipients, and, therefore, that TrED could provide a promising clinical strategy for GVHD prophylaxis.

Original languageEnglish (US)
JournalJCI insight
Volume3
Issue number20
DOIs
StatePublished - Oct 18 2018

Fingerprint

Cyclophosphamide
Tissue Donors
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Transplants
Therapeutics
Receptors, Tumor Necrosis Factor, Member 25
Weight Loss
Adoptive Transfer
Allografts
Morbidity
Skin
Survival
Mortality

Keywords

  • Bone marrow transplantation
  • Immunology
  • T cells
  • Transplantation

Cite this

Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models. / Wolf, Dietlinde; Bader, Cameron S.; Barreras, Henry; Copsel, Sabrina; Pfeiffer, Brent; Lightbourn, Casey O.; Altman, Norman H.; Komanduri, Krishna V; Levy, Robert B.

In: JCI insight, Vol. 3, No. 20, 18.10.2018.

Research output: Contribution to journalArticle

Wolf, Dietlinde ; Bader, Cameron S. ; Barreras, Henry ; Copsel, Sabrina ; Pfeiffer, Brent ; Lightbourn, Casey O. ; Altman, Norman H. ; Komanduri, Krishna V ; Levy, Robert B. / Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models. In: JCI insight. 2018 ; Vol. 3, No. 20.
@article{3ce7ed1fea66426e962c17e08e1a95a7,
title = "Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models",
abstract = "Posttransplant cyclophosphamide (PTCy) has been found to be effective in ameliorating acute graft-versus-host disease (GVHD) in patients following allogeneic hematopoietic stem cell transplantation (aHSCT). Adoptive transfer of high numbers of donor Tregs in experimental aHSCT has shown promise as a therapeutic modality for GVHD regulation. We recently described a strategy for in vivo Treg expansion targeting two receptors: TNFRSF25 and CD25. To date, there have been no direct comparisons between the use of PTCy and Tregs regarding outcome and immune reconstitution within identical groups of transplanted mice. Here, we assessed these two strategies and found both decreased clinical GVHD and improved survival long term. However, recipients transplanted with Treg-expanded donor cells (TrED) exhibited less weight loss early after HSCT. Additionally, TrED recipients demonstrated less thymic damage, significantly more recent thymic emigrants, and more rapid lymphoid engraftment. Three months after HSCT, PTCy-treated and TrED recipients showed tolerance to F1 skin allografts and comparable immune function. Overall, TrED was found superior to PTCy with regard to weight loss early after transplant and initial lymphoid engraftment. Based on these findings, we speculate that morbidity and mortality after transplant could be diminished following TrED transplant into aHSCT recipients, and, therefore, that TrED could provide a promising clinical strategy for GVHD prophylaxis.",
keywords = "Bone marrow transplantation, Immunology, T cells, Transplantation",
author = "Dietlinde Wolf and Bader, {Cameron S.} and Henry Barreras and Sabrina Copsel and Brent Pfeiffer and Lightbourn, {Casey O.} and Altman, {Norman H.} and Komanduri, {Krishna V} and Levy, {Robert B}",
year = "2018",
month = "10",
day = "18",
doi = "10.1172/jci.insight.121717",
language = "English (US)",
volume = "3",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "20",

}

TY - JOUR

T1 - Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models

AU - Wolf, Dietlinde

AU - Bader, Cameron S.

AU - Barreras, Henry

AU - Copsel, Sabrina

AU - Pfeiffer, Brent

AU - Lightbourn, Casey O.

AU - Altman, Norman H.

AU - Komanduri, Krishna V

AU - Levy, Robert B

PY - 2018/10/18

Y1 - 2018/10/18

N2 - Posttransplant cyclophosphamide (PTCy) has been found to be effective in ameliorating acute graft-versus-host disease (GVHD) in patients following allogeneic hematopoietic stem cell transplantation (aHSCT). Adoptive transfer of high numbers of donor Tregs in experimental aHSCT has shown promise as a therapeutic modality for GVHD regulation. We recently described a strategy for in vivo Treg expansion targeting two receptors: TNFRSF25 and CD25. To date, there have been no direct comparisons between the use of PTCy and Tregs regarding outcome and immune reconstitution within identical groups of transplanted mice. Here, we assessed these two strategies and found both decreased clinical GVHD and improved survival long term. However, recipients transplanted with Treg-expanded donor cells (TrED) exhibited less weight loss early after HSCT. Additionally, TrED recipients demonstrated less thymic damage, significantly more recent thymic emigrants, and more rapid lymphoid engraftment. Three months after HSCT, PTCy-treated and TrED recipients showed tolerance to F1 skin allografts and comparable immune function. Overall, TrED was found superior to PTCy with regard to weight loss early after transplant and initial lymphoid engraftment. Based on these findings, we speculate that morbidity and mortality after transplant could be diminished following TrED transplant into aHSCT recipients, and, therefore, that TrED could provide a promising clinical strategy for GVHD prophylaxis.

AB - Posttransplant cyclophosphamide (PTCy) has been found to be effective in ameliorating acute graft-versus-host disease (GVHD) in patients following allogeneic hematopoietic stem cell transplantation (aHSCT). Adoptive transfer of high numbers of donor Tregs in experimental aHSCT has shown promise as a therapeutic modality for GVHD regulation. We recently described a strategy for in vivo Treg expansion targeting two receptors: TNFRSF25 and CD25. To date, there have been no direct comparisons between the use of PTCy and Tregs regarding outcome and immune reconstitution within identical groups of transplanted mice. Here, we assessed these two strategies and found both decreased clinical GVHD and improved survival long term. However, recipients transplanted with Treg-expanded donor cells (TrED) exhibited less weight loss early after HSCT. Additionally, TrED recipients demonstrated less thymic damage, significantly more recent thymic emigrants, and more rapid lymphoid engraftment. Three months after HSCT, PTCy-treated and TrED recipients showed tolerance to F1 skin allografts and comparable immune function. Overall, TrED was found superior to PTCy with regard to weight loss early after transplant and initial lymphoid engraftment. Based on these findings, we speculate that morbidity and mortality after transplant could be diminished following TrED transplant into aHSCT recipients, and, therefore, that TrED could provide a promising clinical strategy for GVHD prophylaxis.

KW - Bone marrow transplantation

KW - Immunology

KW - T cells

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85063240248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063240248&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.121717

DO - 10.1172/jci.insight.121717

M3 - Article

VL - 3

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 20

ER -